Fase 3-studie af ProstAtak®-immunterapi med standard strålebehandling til lokaliseret prostatakræft (PrTK03)
Et randomiseret kontrolleret forsøg med ProstAtak® som adjuvans til up-front strålebehandling til lokaliseret prostatakræft
The purpose of this study is to evaluate the effectiveness of ProstAtak® immunotherapy in combination with radiation therapy for patients with intermediate-high risk localized prostate cancer. ProstAtak kills tumor cells and stimulates a cancer vaccine effect. Killing tumor cells in an immune stimulatory environment induces the body's immune system to detect and destroy cancer cells. ProstAtak has shown synergy with radiation without added toxicity and lower than expected recurrence rates in previous clinical trials. The hypothesis is that ProstAtak can lead to improvement in the clinical outcome for patients with prostate cancer. Participants will be randomized to the ProstAtak or control arm at a 2:1 ratio. Both arms receive standard external beam radiation therapy. Short-term androgen deprivation therapy may be given but is not required.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
Arizona
-
Gilbert, Arizona, Forenede Stater, 85297
- Arizona Center for Cancer Care - Gilbert
-
Glendale, Arizona, Forenede Stater, 85308
- Arizona Urology Specialists
-
Peoria, Arizona, Forenede Stater, 85381
- Arizona Center for Cancer Care - Peoria
-
Phoenix, Arizona, Forenede Stater, 85027
- Arizona Center for Cancer Care - Deer Valley
-
Phoenix, Mesa, Scottsdale, Sedona, Arizona, Forenede Stater, 85260
- Arizona Oncology Services Foundation
-
Scottsdale, Arizona, Forenede Stater, 85251
- Arizona Center for Cancer Care - Osborne
-
Scottsdale, Arizona, Forenede Stater, 85258
- Arizona Center for Cancer Care - Shea
-
Surprise, Arizona, Forenede Stater, 85374
- Arizona Center for Cancer Care - Surprise
-
Tucson, Arizona, Forenede Stater, 85723
- Southern Arizona VA Health Care System
-
-
California
-
Mather, California, Forenede Stater, 95655
- VA Northern California Health Care System
-
Tustin, California, Forenede Stater, 92780
- Precision Radiation Oncology
-
-
Colorado
-
Glenwood Springs, Colorado, Forenede Stater, 81601
- Valley View Hospital
-
Lakewood, Colorado, Forenede Stater, 80228
- Colorado Clinical Research
-
Parker, Colorado, Forenede Stater, 80134
- Advanced Urology
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20016
- Sibley Memorial Hospital
-
-
Florida
-
Fort Lauderdale, Florida, Forenede Stater, 33324
- 21st Century Oncology
-
Lakewood Rch, Florida, Forenede Stater, 34202
- 21st Century Oncology
-
Naples, Florida, Forenede Stater, 34102
- 21st Century Oncology
-
Plantation, Florida, Forenede Stater, 33324
- 21st Century Oncology
-
Pompano Beach, Florida, Forenede Stater, 33060
- Clinical Research Center of Florida
-
Tampa, Florida, Forenede Stater, 33615
- Florida Urology Partners
-
Tampa, Florida, Forenede Stater, 33612
- James A. Haley Veteran's Hospital
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60637
- The University of Chicago
-
Chicago, Illinois, Forenede Stater, 60612
- Jesse Brown VA Medical Center
-
New Lenox, Illinois, Forenede Stater, 60451
- Silver Cross Hospital
-
-
Louisiana
-
New Orleans, Louisiana, Forenede Stater, 70119
- Southeast Louisiana Veterans Health Care System
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21201
- VA Maryland Health Care System
-
Baltimore, Maryland, Forenede Stater, 21204
- Chesapeake Urology Research Associates
-
Baltimore, Maryland, Forenede Stater, 21231
- The Johns Hopkins University School of Medicine, The Sidney Kimmel Comprehensive Cancer Center
-
Bethesda, Maryland, Forenede Stater, 20889
- Walter Reed National Military Medical Center
-
-
Massachusetts
-
Worcester, Massachusetts, Forenede Stater, 01605
- University of Massachusetts Medical School
-
-
Missouri
-
Kansas City, Missouri, Forenede Stater, 64128
- Kansas City VA Medical Center
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68114
- Adult & Pediatric Urology, P.C.
-
-
Nevada
-
Las Vegas, Nevada, Forenede Stater, 89144
- Sheldon Freedman MD, Ltd.
-
Reno, Nevada, Forenede Stater, 89502
- VA Sierra Nevada Health Care System
-
-
New Jersey
-
Cherry Hill, New Jersey, Forenede Stater, 08003
- New Jersey Urology - Cherry Hill
-
Englewood, New Jersey, Forenede Stater, 07631
- New Jersey Urology - Englewood
-
Millburn, New Jersey, Forenede Stater, 07041
- New Jersey Urology - Milburn
-
Saddle Brook, New Jersey, Forenede Stater, 07663
- New Jersey Urology - Saddle Brook
-
West Orange, New Jersey, Forenede Stater, 07052
- New Jersey Urology - West Orange
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87131
- University of New Mexico Cancer Center
-
Albuquerque, New Mexico, Forenede Stater, 87109
- New Mexico Oncology Hematology Consultants (NMOHC)
-
-
New York
-
North Hills, New York, Forenede Stater, 11042
- Advanced Radiation Centers of New York (Integrated Medical Professionals)
-
Syracuse, New York, Forenede Stater, 13210
- Associated Medical Professionals of NY, PLLC
-
The Bronx, New York, Forenede Stater, 10468
- James J. Peters VA Medical Center
-
-
North Carolina
-
Durham, North Carolina, Forenede Stater, 27705
- Durham VA Health Care System
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45220
- Cincinnati VA Medical Center
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97239
- VA Portland Health Care System
-
Springfield, Oregon, Forenede Stater, 97477
- Oregon Urology Institute
-
-
Pennsylvania
-
Bala-Cynwyd, Pennsylvania, Forenede Stater, 19004
- MidLantic Urology
-
Philadelphia, Pennsylvania, Forenede Stater, 19111-2497
- Fox Chase Cancer Center
-
-
South Carolina
-
Charleston, South Carolina, Forenede Stater, 29401
- Ralph H. Johnson Veterans Affairs Medical Center
-
Myrtle Beach, South Carolina, Forenede Stater, 29572
- Carolina Urologic Research Center, LLC
-
-
Texas
-
Austin, Texas, Forenede Stater, 78705
- Urology Austin
-
Austin, Texas, Forenede Stater, 78758
- Austin Urology Institute
-
Austin, Texas, Forenede Stater, 78759
- Austin Urology Institute - Northwest Austin Cancer Center
-
Dallas, Texas, Forenede Stater, 75216
- VA North Texas Health Care System
-
Dallas, Texas, Forenede Stater, 75231
- Urology Clinics of North Texas
-
Houston, Texas, Forenede Stater, 77030
- Dr. Irving Fishman's Office
-
Houston, Texas, Forenede Stater, 77070
- Houston Willowbrook Radiation Oncology
-
Houston, Texas, Forenede Stater, 77074
- Dr. Ned Stein's Office
-
San Antonio, Texas, Forenede Stater, 78229
- The University of Texas Health Science Center at San Antonio
-
San Antonio, Texas, Forenede Stater, 78229-4404
- South Texas San Antonio VA Healthcare System
-
The Woodlands, Texas, Forenede Stater, 77385
- Texas Urology Specialists-The Woodlands
-
The Woodlands, Texas, Forenede Stater, 77385
- The Methodist Hospital - The Woodlands
-
Tomball, Texas, Forenede Stater, 77375
- Texas Urology Specialists
-
-
Virginia
-
Alexandria, Virginia, Forenede Stater, 22311
- Potomac Urology Center
-
Richmond, Virginia, Forenede Stater, 23249
- Hunter Holmes McGuire VA Medical Center
-
Salem, Virginia, Forenede Stater, 24153
- Salem VA Medical Center
-
Virginia Beach, Virginia, Forenede Stater, 23462
- Urology of Virginia, PLLC
-
-
Washington
-
Gig Harbor, Washington, Forenede Stater, 98335
- MultiCare Regional Cancer Center - Gig Harbor
-
Tacoma, Washington, Forenede Stater, 98405
- MultiCare Regional Cancer Center - Tacoma
-
-
-
-
Puerto Rico
-
San Juan, Puerto Rico, Puerto Rico, 00921
- VA Caribbean Healthcare System
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria include:
-
Localized prostate cancer meeting the NCCN criteria of Intermediate Risk or patients having only one NCCN high-risk feature
- NCCN Intermediate Risk is defined as having at least one of the following: PSA 10-20 ng/ml, Gleason score =7, T2b-T2c
- High Risk with a single high risk feature is defined as having only one of the following: PSA>20 ng/ml, Gleason score 8-10, or T3a
- Excluded are those in the following risk groups: Low risk; High risk with more than 1 high risk factor; Locally advanced/very high risk=T3b-T4; Metastatic: N1 or M1
-
Planning to undergo standard prostate-only external beam radiation therapy
-
ECOG Performance Status 0-2
Exclusion Criteria include:
- Liver disease, including known cirrhosis or active hepatitis
- Patients on systemic corticosteroids (>10mg prednisone per day) or other immunosuppressive drugs
- Known HIV+ patients
- Regional lymph node involvement or distant metastases
- Patients planning to receive whole pelvic irradiation
- Prior treatment for prostate cancer, except TURP or ADT. For ADT, it may only be given for a maximum of 6 months
- Patients who had or plan to have orchiectomy as the form of hormonal ablation
- Known sensitivity or allergic reactions to acyclovir or valacyclovir
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: ProstAtak®
Aglatimagene besadenovec (CAN-2409) + valacyclovir + radiation therapy +/- ADT |
Patients will receive three courses of ProstAtak® each consisting of aglatimagene besadenovec injection + oral valacyclovir. AdV-tk injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows:
The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each AdV-tk injection. Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification.
Andre navne:
|
|
Placebo komparator: Control
Placebo + valacyclovir + radiation therapy +/- ADT |
Patients will receive three courses each consisting of placebo injection + oral valacyclovir. Placebo injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows:
The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each placebo injection. Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Sygdomsfri overlevelse defineret som tiden fra randomisering til datoen for den første fejlhændelse vil blive sammenlignet for ProstAtak®-armen versus placebo-kontrolarmen. Analyserne vil være baseret på intentionen om at behandle befolkningen.
Tidsramme: Vurderet ved hvert besøg hver 6. måned til og med år 5, indtil hændelsen indtræffer.
|
Vurderet ved hvert besøg hver 6. måned til og med år 5, indtil hændelsen indtræffer.
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Prostatacancer-specifik overlevelse og samlet overlevelse vil blive sammenlignet for ProstAtak®-armen versus placebo-kontrolarmen.
Tidsramme: Vurderes ved hvert besøg hver 6. måned til og med år 5, hvorefter den langsigtede opfølgning af generel helbredstilstand vil fortsætte årligt.
|
Vurderes ved hvert besøg hver 6. måned til og med år 5, hvorefter den langsigtede opfølgning af generel helbredstilstand vil fortsætte årligt.
|
|
PSA-nadir vil blive sammenlignet for ProstAtak®-armen versus placebo-kontrolarmen.
Tidsramme: Vurderet ved hvert besøg hver 6. måned til og med år 5.
|
Vurderet ved hvert besøg hver 6. måned til og med år 5.
|
|
Patientrapporterede sundhedsrelaterede livskvalitetsresultater vil blive indsamlet ved hjælp af det udvidede prostatacancerindeks sammensatte (EPIC-26) spørgeskema. Ændringen i QOL over tid vil blive sammenlignet for ProstAtak®-armen versus placebo-kontrolarmen.
Tidsramme: Vurderet ved baseline og 3, 6, 12, 18 og 24 måneder efter afslutning af stråling.
|
Vurderet ved baseline og 3, 6, 12, 18 og 24 måneder efter afslutning af stråling.
|
|
Sikkerhedsprofilen vil være karakteriseret ved indsamling af uønskede hændelser og laboratorieværdier under behandlingsfasen (indtil bestrålingen er afsluttet). Data om senvirkninger vil blive indsamlet efter færdiggørelse af stråling.
Tidsramme: Vurderet ved hvert besøg og løbende gennem hele undersøgelsen.
|
Vurderet ved hvert besøg og løbende gennem hele undersøgelsen.
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Anslået)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Genitale sygdomme
- Genitale neoplasmer, mandlige
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Neoplasmer
- Kønssygdomme, mandlige
- Prostatasygdomme
- Mandlige urogenitale sygdomme
- Prostatiske neoplasmer
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ring
- Guanine
- Hypoxanthines
- Purinoner
- Puriner
- Acyclovir
- Valacyclovir
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- PrTK03
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .